LIPTRUZET

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).

How it works

Ezetimibe inhibits intestinal cholesterol absorption at the brush border of the small intestine, while simvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis; combination lowers plasma LDL-C.

What the body does with it

Metabolism	Ezetimibe: glucuronidation (UGT1A1, UGT1A3, UGT2B15); simvastatin: CYP3A4 (primary), CYP3A5; both undergo extensive first-pass metabolism.
Excretion	Rosuvastatin: 90% fecal, 10% renal. Ezetimibe: 78% fecal as unchanged drug, 11% renal as glucuronide conjugate.
Half-life	Rosuvastatin: 19 hours. Ezetimibe: 22 hours for ezetimibe-glucuronide. Allows once-daily dosing.
Protein binding	Rosuvastatin: 88% bound to albumin. Ezetimibe: >90% bound to albumin.
Volume of Distribution	Rosuvastatin: 1.1 L/kg. Ezetimibe: 5.8 L/kg (apparent) due to extensive enterohepatic recirculation.
Bioavailability	Rosuvastatin: 20% oral. Ezetimibe: 35-65% unknown absolute; systemic exposure increased with food.
Onset of Action	Oral: LDL-C reduction begins within 1 week, maximal by 4 weeks.
Duration of Action	Duration of lipid-lowering effect persists with continued daily dosing; steady state achieved by 2 weeks for rosuvastatin and 3-4 weeks for ezetimibe.

Classification & Brands

Dosing & administration

Lipoprotein(a) apheresis is performed at a flow rate of 1-2 mL/min for 60-90 minutes, repeated every 2-4 weeks. For atorvastatin component: initiate at 10-20 mg orally once daily, titrate up to 80 mg once daily based on response.

Dosage form	TABLET
Renal impairment	Atorvastatin: no adjustment required in mild to moderate renal impairment; avoid CrCl <30 mL/min. Lipoprotein(a) apheresis: no renal adjustment needed.
Liver impairment	Atorvastatin: contraindicated in active liver disease or unexplained ALT/AST >3x ULN. Child-Pugh Class A: no dose adjustment; Class B: use with caution; Class C: contraindicated. Lipoprotein(a) apheresis: no hepatic adjustment.
Pediatric use	Atorvastatin: children ≥10 years: 10 mg orally once daily, max 20 mg once daily. Lipoprotein(a) apheresis: not established in pediatric population.
Geriatric use	Atorvastatin: start at lower initial dose (10 mg) due to increased risk of myopathy; titrate cautiously. Lipoprotein(a) apheresis: no specific dose adjustment, but consider tolerance to extracorporeal volume.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).

Breastfeeding	Excreted in human milk; M/P ratio 1.2. Potential for serious adverse reactions in nursing infants (renal toxicity, oligohydramnios). Discontinue breastfeeding or discontinue drug.
Teratogenic Risk	Pregnancy Category X. First trimester: high risk of severe fetal cardiac defects, orofacial clefts, neural tube defects. Second and third trimesters: risk of fetal renal anomalies, oligohydramnios, premature closure of ductus arteriosus. Contraindicated in pregnancy.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Simvastatin component: increased risk of myopathy/rhabdomyolysis when used with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone); contraindicated with such drugs; also contraindicated with gemfibrozil, cyclosporine, danazol.

Side Effect Profile

Serious Effects

Absolute Contraindications

Active liver disease; unexplained persistent transaminase elevations; pregnancy; nursing mothers; concomitant use with potent CYP3A4 inhibitors, gemfibrozil, cyclosporine, danazol; hypersensitivity to any component.

Clinical Precautions

Precautions

Myopathy/rhabdomyolysis risk; hepatic enzyme elevations; contraindicated with strong CYP3A4 inhibitors; pregnancy category X; avoid heavy alcohol use; monitor liver function before and after initiation; caution in patients with predisposing factors for myopathy.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LIPTRUZET

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).

How it works

What the body does with it

Metabolism	Ezetimibe: glucuronidation (UGT1A1, UGT1A3, UGT2B15); simvastatin: CYP3A4 (primary), CYP3A5; both undergo extensive first-pass metabolism.
Excretion	Rosuvastatin: 90% fecal, 10% renal. Ezetimibe: 78% fecal as unchanged drug, 11% renal as glucuronide conjugate.
Half-life	Rosuvastatin: 19 hours. Ezetimibe: 22 hours for ezetimibe-glucuronide. Allows once-daily dosing.
Protein binding	Rosuvastatin: 88% bound to albumin. Ezetimibe: >90% bound to albumin.
Volume of Distribution	Rosuvastatin: 1.1 L/kg. Ezetimibe: 5.8 L/kg (apparent) due to extensive enterohepatic recirculation.
Bioavailability	Rosuvastatin: 20% oral. Ezetimibe: 35-65% unknown absolute; systemic exposure increased with food.
Onset of Action	Oral: LDL-C reduction begins within 1 week, maximal by 4 weeks.
Duration of Action	Duration of lipid-lowering effect persists with continued daily dosing; steady state achieved by 2 weeks for rosuvastatin and 3-4 weeks for ezetimibe.

Classification & Brands

Dosing & administration

Dosage form	TABLET
Renal impairment	Atorvastatin: no adjustment required in mild to moderate renal impairment; avoid CrCl <30 mL/min. Lipoprotein(a) apheresis: no renal adjustment needed.
Liver impairment	Atorvastatin: contraindicated in active liver disease or unexplained ALT/AST >3x ULN. Child-Pugh Class A: no dose adjustment; Class B: use with caution; Class C: contraindicated. Lipoprotein(a) apheresis: no hepatic adjustment.
Pediatric use	Atorvastatin: children ≥10 years: 10 mg orally once daily, max 20 mg once daily. Lipoprotein(a) apheresis: not established in pediatric population.
Geriatric use	Atorvastatin: start at lower initial dose (10 mg) due to increased risk of myopathy; titrate cautiously. Lipoprotein(a) apheresis: no specific dose adjustment, but consider tolerance to extracorporeal volume.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIPTRUZET (LIPTRUZET).

Breastfeeding	Excreted in human milk; M/P ratio 1.2. Potential for serious adverse reactions in nursing infants (renal toxicity, oligohydramnios). Discontinue breastfeeding or discontinue drug.
Teratogenic Risk	Pregnancy Category X. First trimester: high risk of severe fetal cardiac defects, orofacial clefts, neural tube defects. Second and third trimesters: risk of fetal renal anomalies, oligohydramnios, premature closure of ductus arteriosus. Contraindicated in pregnancy.
Fetal Monitoring